A Study of ARRY-334543 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive
investigational study drug ARRY-334543.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug (2 dosing schedules will be evaluated) in order to achieve the highest dose possible
that will not cause unacceptable side effects. Approximately 70 patients from the US and
Canada will be enrolled in Part 1 (Completed).
In the second part of the study, patients will receive the best dose(s) and schedule(s) of
study drug determined from the first part of the study and will be followed to see what side
effects the study drug causes and what effectiveness it has, if any, in treating the cancer.
Approximately 40 patients from the US and Canada will be enrolled in Part 2 (Completed).
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer